Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | IDH2 | P48735 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21159355 | 0.93 | EGFR (0.64) | EGFRABCG2TSHRHTTKDM4E | |
| SCHEMBL3001623 | 0.82 | EGFR (1.00) | EGFRABCG2TSHRHTTBRAF | |
| SCHEMBL15184021 | 0.82 | EGFR (0.67) | EGFRABCG2TSHRHTTKDM4E | |
| SCHEMBL1095749 | 0.81 | EGFR (0.58) | EGFRABCG2TSHRHTTKDM4E | |
| SCHEMBL2261546 | 0.81 | EGFR (0.64) | EGFRABCG2TSHRHTTKDM4E | |
| SCHEMBL4239042 | 0.81 | THRB (0.68) | EGFRABCG2TSHRHTTKDM4E | |
| SCHEMBL20119339 | 0.80 | EGFR (0.58) | EGFRABCG2TSHRHTTKDM4E | |
| SCHEMBL30754777 | 0.80 | LMNA (0.65) | EGFRABCG2TSHRHTTTHRB | |
| SCHEMBL16882281 | 0.80 | EGFR (0.82) | EGFRABCG2TSHRHTT | |
| SCHEMBL6837287 | 0.80 | EGFR (1.00) | EGFRABCG2TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197902-A1 | Use of Pyrimidine Compounds in the Preparation of Parasiticides | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| US-20070155757-A1 | Use of pyrimidine compounds in the preparation of parasiticides | FRUCHTEL JORG | 2007-07-05 | — | — | US | disclosed |
| EP-1725539-A1 | USE OF PYRIMIDINE COMPOUNDS IN THE PREPARATION OF PARASITICIDES | Novartis AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085211-A1 | USE OF PYRIMIDINE COMPOUNDS IN THE PREPARATION OF PARASITICIDES | NOVARTIS AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| EP-1574502-A1 | Use of pyrimidine compounds in the preparation of parasiticides | Novartis AG (CH) | 2005-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197902-A1 | Use of Pyrimidine Compounds in the Preparation of Parasiticides | TYMP, TYMS, P2RX1 | EGFR 4681/4885ABCG2 148/4885TSHR 1360/4885 |
| US-20070155757-A1 | Use of pyrimidine compounds in the preparation of parasiticides | TYMP, TYMS, P2RX1 | EGFR 4681/4885ABCG2 148/4885TSHR 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.